| Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo: α:-Enolase and Annexin AI M Bruschi, RA Sinico, G Moroni, F Pratesi, P Migliorini, M Galetti, C Murtas, ... Journal of the American Society of Nephrology 25 (11), 2483-2498, 2014 | 116 | 2014 |
| Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones A Cavazzoni, MA Bonelli, C Fumarola, S La Monica, K Airoud, R Bertoni, ... Cancer letters 323 (1), 77-87, 2012 | 110 | 2012 |
| Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines S La Monica, M Galetti, RR Alfieri, A Cavazzoni, A Ardizzoni, M Tiseo, ... Biochemical pharmacology 78 (5), 460-468, 2009 | 104 | 2009 |
| Neutrophil extracellular traps profiles in patients with incident systemic lupus erythematosus and lupus nephritis M Bruschi, A Bonanni, A Petretto, A Vaglio, F Pratesi, L Santucci, ... The Journal of rheumatology 47 (3), 377-386, 2020 | 101 | 2020 |
| Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis L Manenti, A Vaglio, E Gnappi, U Maggiore, L Allegri, M Allinovi, ... Clinical Journal of the American Society of Nephrology 10 (12), 2143-2151, 2015 | 86 | 2015 |
| Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial D Gianfreda, M Nicastro, M Galetti, F Alberici, D Corradi, G Becchi, ... Blood, The Journal of the American Society of Hematology 126 (10), 1163-1171, 2015 | 85 | 2015 |
| Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines A Cavazzoni, RR Alfieri, C Carmi, V Zuliani, M Galetti, C Fumarola, ... Molecular cancer therapeutics 7 (2), 361-370, 2008 | 84 | 2008 |
| Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling C Fumarola, C Caffarra, S La Monica, M Galetti, RR Alfieri, A Cavazzoni, ... Breast cancer research and treatment 141, 67-78, 2013 | 81 | 2013 |
| Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells D Cretella, C Fumarola, M Bonelli, R Alfieri, S La Monica, G Digiacomo, ... Scientific reports 9 (1), 13014, 2019 | 77 | 2019 |
| Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance D Cretella, F Saccani, F Quaini, C Frati, C Lagrasta, M Bonelli, C Caffarra, ... Molecular cancer 13, 1-12, 2014 | 77 | 2014 |
| Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion C Carmi, A Cavazzoni, S Vezzosi, F Bordi, F Vacondio, C Silva, S Rivara, ... Journal of medicinal chemistry 53 (5), 2038-2050, 2010 | 77 | 2010 |
| Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens M Bruschi, M Galetti, RA Sinico, G Moroni, A Bonanni, A Radice, A Tincani, ... Journal of the American Society of Nephrology 26 (8), 1905-1924, 2015 | 75 | 2015 |
| Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation S La Monica, D Madeddu, M Tiseo, V Vivo, M Galetti, D Cretella, M Bonelli, ... Journal of Thoracic Oncology 11 (7), 1051-1063, 2016 | 68 | 2016 |
| Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines M Galetti, PG Petronini, C Fumarola, D Cretella, S La Monica, M Bonelli, ... PloS one 10 (11), e0141795, 2015 | 68 | 2015 |
| 5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line V Zuliani, C Carmi, M Rivara, M Fantini, A Lodola, F Vacondio, F Bordi, ... European journal of medicinal chemistry 44 (9), 3471-3479, 2009 | 61 | 2009 |
| Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines RR Alfieri, M Galetti, S Tramonti, R Andreoli, P Mozzoni, A Cavazzoni, ... Molecular cancer 10, 1-14, 2011 | 60 | 2011 |
| Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires A Cacchioli, F Ravanetti, R Alinovi, S Pinelli, F Rossi, M Negri, E Bedogni, ... Nano Letters 14 (8), 4368-4375, 2014 | 58 | 2014 |
| Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC S La Monica, R Minari, D Cretella, L Flammini, C Fumarola, M Bonelli, ... Journal of Experimental & Clinical Cancer Research 38, 1-12, 2019 | 52 | 2019 |
| Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines A Cavazzoni, RR Alfieri, D Cretella, F Saccani, L Ampollini, M Galetti, ... Molecular cancer 11, 1-14, 2012 | 50 | 2012 |
| Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification S La Monica, C Caffarra, F Saccani, E Galvani, M Galetti, C Fumarola, ... PloS one 8 (10), e78656, 2013 | 49 | 2013 |
